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Over-expression of the tyrosine kinase proto-oncogenic receptor
epidermal growth factor receptor (EGFR), has been reported to
occur in many malignancies including gliomas, head and neck
tumours, lung, breast and bladder cancer (Gullick, 1991). It is
associated with a poor prognosis in several tumour types includ-
ing breast cancer (Harris et al, 1992; Salomon et al, 1995).
Rearrangements in the EGFR gene have been reported in cases
where EGFR is amplified. One mutant, EGFR type III
(EGFRvIII), in which there is a deletion of 267 amino acids in the
receptor’s extracellular domain, occurs during malignant progres-
sion (Ekstrand et al, 1992). It is similar to EGFR in its ability to
dimerise and autophosphorylate but is constitutively active and
does not bind EGF (Ekstrand et al, 1994; Schmidt et al, 1998).
EGFRvIII has been observed in 25–60% of gliomas, depending on
the method of screening (Wong et al, 1992; Wikstrand et al, 1995),
and a significant percentage of non-small cell lung (16%) and
breast cancers (27–78%) (Moscatello et al, 1995; Wikstrand et al,
1995) but has not been detected in normal human tissue
(Wikstrand et al, 1995). 
Previous work has indicated a link between EGFR expression
and angiogenesis (Petit et al, 1997). Angiogenesis is a complex
process regulated by stimulatory and inhibitory factors, which
result in the formation of new blood vessels from pre-existing
endothelium. It is essential for progression of tumours beyond
several millimetres in diameter. (Folkman, 1990). EGFR expres-
sion in tumour sections has been shown to have a positive correla-
tion with hot spot microvessel density, a measure of angiogenesis
(De Jong et al, 1998). Vascular endothelial growth factor (VEGF)
is a potent regulator of angiogenesis, acting as a specific mitogen
for endothelial cells, and as such has a major role in tumour-
induced angiogenesis (Fidler and Ellis, 1994). Following treatment
of cells over-expressing EGFR in well oxygenated conditions with
an anti-EGFR antibody, C225, down-regulation of VEGF produc-
tion has been described, suggesting a role for EGFR as an inducer
of VEGF (Petit et al, 1997). In vivo administration of the same
antibody to mice with established epidermoid cancers resulted in
reduced growth and down-regulation of VEGF (Petit et al, 1997). 
Environmental stimuli are known to regulate VEGF. Of these,
hypoxia is one of the best characterized and can transiently upreg-
ulate VEGF (Shweiki et al, 1992). Increased VEGF production has
been documented in cells over-expressing mutant ErbB2/neu
(another EGFR-like oncogenic tyrosine kinase) compared to
untransformed parental cell lines under resting conditions, and is
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further increased by conditions that mimic hypoxia (CoCl2 100
mM) (10). In vitro, VEGF expression has been shown to increase
within 3–6 hours of hypoxic exposure (Levy et al, 1995). Hypoxia
increases VEGF expression acutely through increase in transcrip-
tion and prolongation of mRNA half life (Levy et al, 1995).
Cytokines and growth factors are also known to mediate VEGF
expression (Akagi et al, 1998). However, not all factors increase
expression in all tumour systems and response to known stimula-
tors, including hypoxia, varies between cell lines and with experi-
mental conditions (Scott et al, 1998). 
The signalling pathway by which hypoxia increases VEGF, has
not been fully defined. Tyrosine phosphorylation is a key element
in the signal transduction mediated by EGFR. A number of
proteins are activated by EGFR including ras, which plays a
pivotal role in relaying signals from the cell surface to a cascade of
intracellular serine threonine kinases, resulting in the activation by
phosphorylation of various transcriptional factors (Rak et al, 1995;
Whitmarsh and Davis, 1996). Whilst ras appears to be important in
the regulation of VEGF (Feldkamp et al, 1999), other oncogenes,
tumour suppressor genes and growth factors must also play a role
as evidenced by the finding that virtually all colon cancer cells
express VEGF, yet only 50% have a mutant k-ras allele (Rak et al,
1995). Phosphatidylinositol-3-kinase (PI3 kinase), which is
constitutively active in EGFRvIII transformed cells (Moscatello 
et al, 1998), also appears to be important. PI3 kinase plays an
important role in many cellular processes including mitogenesis
and cell survival. Production of PI3 kinase activates protein kinase
B (PKB)/Akt. The survival signal mediated by various growth
factors and cytokines may be dependent on the PI3 kinase/PKB
signal transduction pathway (Gerber et al, 1998). 
Because of differences in effect of mutant EGFRvIII on in vivo
and in vitro growth (Nishikawa et al, 1994), we have used NIH3T3
cells transfected with full length or mutated EGFRvIII, to investi-
gate modulation of VEGF production by environmental stimuli.
NIH3T3 cells were chosen based on their known low expression
of VEGF and low levels of activated Ras (Guha et al, 1997)
thereby allowing the effects of mutant EGFR on the expression of
VEGF to be investigated on a low Ras background, without
multiple other pathways and thus to elucidate the role of the
mutant. The role of PI3 kinase and its down-stream target Akt3
were investigated using specific PI3 kinase inhibitors. The role of
growth factors in increasing VEGF was also analysed using EGF,
and IGF-1, a known stimulator of VEGF in other tumour systems. 
MATERIALS AND METHODS 
Materials 
Recombinant human insulin-like growth factor-1 (IGF-1) was
purchased from Life Technologies (GIBCO BRL, Paisley, UK),
and epidermal growth factor (EGF) and PI3 kinase inhibitors LY
294002 and wortmannin, from Sigma (Louis, MO). 
Antibodies 
EGFR1, a mouse monoclonal antibody which interacts only with
full length human EGFR (Waterfield et al, 1982), and DH8.3 an
IgG1 antibody which recognizes mutant but not full length EGFR
(Hills et al, 1995), were obtained from ICRF research monoclonal
antibody facility (Clare Hall, Lincoln’s Inn Fields, London, UK). 
Cell lines 
The generation of stably transfected NIH3T3 cell lines, DH-
EGFR-E (which expresses full length EGFR cDNA), DH-E∆ 801-P
(expresses truncated receptor), and DH-L-12 (empty vector), have
been previously described (Hills et al, 1995). 
Cell lines were maintained in Dulbecco’s modified Eagles
medium (DMEM; Clare Hall Laboratories, Imperial Cancer
Research Fund, South Mimms, UK), supplemented by 10% heat-
inactivated fetal bovine serum (FBS, Helena Bioscience,
Sunderland, UK) and kept at 37˚C in a humidified atmosphere of
air containing 5% CO2. Cells were maintained in the logarithmic
phase of growth by passaging 2–3 times weekly. Staining of
methanol/acetone fixed cells with Hoescht 33258 was used to
confirm that cell lines were free from mycoplasma. 
Hypoxic (5% CO2, 0.1% O2, 94.9% N2) conditions were gener-
ated in a hypoxic incubator (Cell House 170, Heto-Holten (UK)
Ltd, Surrey, UK). 
Flow cytometry 
Antigen expression was confirmed via flow cytometry. In brief,
following a 1 hour incubation with 3% fetal bovine serum in 
phosphate-buffered saline (FBS-PBS) to block non-specific antibody
binding, cells were incubated with the relevant primary antibody
(EGFR1, or DH8.3) for 1 hour, followed by fluorescein-
conjugated F(ab’)2 rabbit anti-mouse immunoglobulins (1:20
dilution; DAKO, High Wycombe, UK). Binding of primary anti-
body was analysed using a Becton Dickenson FACS machine. 
Growth curves 
In vitro 
DH-EGFR-E and DH-E∆ 801-P cells were plated in triplicate at
the same starting concentration, in media containing 10% FBS.
Cells were harvested on days one to five of culture, and counted on
an automated particle and size analyser (Coulter Z-2, Coulter
Electronics Ltd, Luton, UK). 
In vivo 
Using a previously established method (Hills et al, 1995), tumours
were established in BALB/c nu/nu mice by subcutaneous injection
into the flank of 5 ´ 106 cells of each of the cell lines described
above. Tumours were measured in the longest axis (L) and the axis
at 90˚ to the longest axis (W) by slide caliper 2–3 times a week.
Tumour volume (TV) in cubic millimetres was calculated by the
formula volume = (L ´ W2)/2 (Inaba et al, 1989) and the mean
tumour volume (± standard deviation) for each treatment group
calculated and graphed. 
Measurement of VEGF protein levels 
Cells were plated at a density of 2 ´ 105 cells 2 ml media–1 well–1 in
6-well culture plates (Falcon, Becton Dickinson Labware, NJ,
USA) and allowed to grow to desired confluence. At this time the
culture medium was aspirated and replaced with fresh assay
medium with or without inhibitors of PI3 kinase, IGF-1, EGF or
blocking antibody (DH8.3). Following 16 hours hypoxia (0.1%
O2) or normoxia, medium was collected, cellular debris removed
by centrifugation, and medium stored at –20˚C until VEGF quan-
tification. Levels of VEGF in conditioned medium were quantified1324 K Clarke et al
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using a commercially available mouse VEGF ELISA kit (R&D
Systems, Minneapolis, MN). Results between wells were stan-
dardized according to the cell number per well as measured using
an automated (Coulter) cell counter. 
Effect of confluence and % FBS on VEGF secretion 
Cells were plated in triplicate in 6-well plates at increasing cell densi-
ties. When the wells with the highest number of cells reached 90%
confluence, plates were processed for VEGF in the usual manner. At
the end of normoxic or hypoxic incubation cells were removed with
PBS/EDTA and cell count determined via a Coulter counter. 
To assess the effect of FBS, cells were grown to 70% confluence
in medium containing 10% FBS, then medium changed to 0, 1 or
10% FBS for 16 hours hypoxia or normoxia. Supernatant was
processed as above. 
Effect of anti-EGFRvIII on xenograft growth 
Commencing on day 0 (D0), where D0 is the day of cell pellet
inoculation, mice were treated with 1 mg per mouse of DH8.3 anti-
body every other day for a total of 4 injections. Antibody was
administered intravenously through the tail vein. The frequency of
dosing was based on the known plasma half life of DH8.3 in vivo
(t 1/2 b 66 hours) (Hills et al, 1995). Control mice received PBS
alone in the same schedule. Mice were measured and tumour
volume calculated as described previously. 
At the completion of the study, xenografts were resected and
frozen for further analysis. VEGF levels in tumour sections were
determined via VEGF ELISA, following homogenization of
samples in a buffer containing 20 mM HEPES, 1.5 mM EDTA,
0.5 mM benzamidine, 0.5 mM phenylmethylsulfonylfluoride and
10 mg ml–1 ovomucoid trypsin inhibitor (Sacks et al, 1993) and
loading of a standardized amount of protein into each well. 
Statistics 
All experiments were carried out in triplicate and repeated at least
twice. Statistical analysis was carried out with Sigmastat for
Windows (Jandel Scientific, San Rafael, CA, USA). Comparisons
between groups were made using the unpaired t-test. 
RESULTS 
Expression of EGFR type III 
Expression of full length or truncated EGFRvIII was confirmed via
flow cytometry (Figure 1). DH-E∆ 801-P was shown to express
EGFRvIII, and the empty vector control expressed neither mutant 
nor full length receptor. DH-EGFR-E expressed full length, but not
mutant EGFR. The levels in DH-E∆ 801-P are similar to those
expressed in glioblastomas with gene amplification (Hills et al, 1995). 
In vitro and in vivo growth 
No significant difference in growth rates in vitro were seen
between cells expressing full length or truncated EGFR when
grown in medium containing 10% FBS. However in vivo there
were dramatic differences between the growth rates, when cell
lines expressing the mutant receptor growing rapidly to form large
tumours (Figure 2). 
Increased VEGF secretion in mutant cells following
hypoxia 
Using cells subconfluent at the beginning of hypoxic incubation,
VEGF secretion by cells expressing mutant EGFR receptor (DH-
E∆ 801-P) was consistently upregulated following exposure to
0.1% hypoxia for the duration of 16 hours (Figure 3). The fold
induction following hypoxia was variable between experiments
(range 3.5–6.6), which may be attributable to minor differences in
confluence (see below) but always achieved statistical signifi-
cance. In contrast cells expressing full length EGFR showed less
than 2-fold increase in VEGF secretion between normoxia and
hypoxia. Baseline (normoxic) levels of VEGF in full length EGFR
expressing cells was similar or slightly elevated compared to
mutant cells. 
Cell confluence and serum starvation can effect VEGF
levels 
In cells expressing the mutant receptor, VEGF secretion into the
supernatant following hypoxic stress increased with confluence,
peaking at 60–70% confluence. Of note hypoxic VEGF levels
were higher at subconfluence (mean ±SD, 2112 pg 106 cells–1 ml–1
± 215) than confluence (1113 pg 106 cells–1 ml–1 ± 112) (P =
0.002). Normoxic VEGF levels did not differ significantly with
degree of confluence. There was a minor effect of percentage 
of FBS in the medium on VEGF secretion. Again differences were
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Figure 1 Flow cytometry of EGFR expression in cell lines. Presence of
EGFRvIII was assessed by the ability to bind DH8.3 (anti-EGFR specific
antibody) (A), and full length EGFR by binding to EGFR1 (B) EGFRvIII expressing cells have enhanced induction of VEGF 1325
British Journal of Cancer (2001) 84(10), 1322–1329 © 2001 Cancer Research Campaign
only significant following hypoxia incubation. Hypoxic VEGF
levels of cells exposed to 0% FBS (1684 pg 106 cells–1 ml–1 ± 48)
were significantly higher than cells grown in 10% FBS (1397 pg
106 cells–1 ml–1 ± 63.5) (P = 0.003). 
In vitro and in vivo effects of anti-EGFR antibody 
In vitro, 10 mg ml–1 of EGFRvIII specific monoclonal antibody
DH8.3 was added to fresh culture medium immediately before
hypoxic incubation. Reduction in hypoxic VEGF levels was seen
in cells expressing mutant EGFR (P = 0.003), but not for cells with
full length receptor (P = 0.07). In vivo, there was suppression of
growth of DH-E∆ 801P (mutant EGFR) xenografts when antibody
was administered intravenously for 4 doses at 48-hour intervals,
for the duration of antibody administration. This was reversible
once antibody was discontinued (Figure 4). 
VEGF levels in tumours in antibody-treated mice showed lower
levels than in the controls. The antibody treated group (n = 7),
range was 33–175 pg mg–1 cytosol protein, median 72 pg mg–1 and
SD 45 pg mg–1, whereas in the controls (n = 7), the range
was 83–220 pg mg–1 cytosol protein, median 110 pg mg–1, SD
49 pg mg–1 (P = 0.08, Mann–Whitney Rank test). 
Mechanism of hypoxic induction of VEGF 
The response to EGF was assessed, and as anticipated there was no
evidence of stimulation of VEGF production by EGFR in mutant
cell lines. However, when added to the culture medium of wild-
type receptor cells there was a significant increase in VEGF
production in EGF-stimulated, compared with unstimulated, cells
(P = 0.01). This increase was only seen in cells incubated under
normoxic conditions with no further increase following hypoxia
(Figure 5). 
Inhibitors of PI3 kinase (wortmannin (5 mm) or LY 294002 (20
mm)) were added to fresh serum-free media immediately prior to
16 hours normoxia or hypoxia. Following hypoxia, induced levels
of VEGF were inhibited in DH-ED801-P cells compared to cells
exposed to hypoxia alone by 63 to 80%. P13 kinase inhibitors did
0 1 02 03 04 05 0
Day post cell innoculation
1500
1000
500
0
DH-EGFR-E
DH-ED 801-P
DL-12
T
u
m
o
u
r
 
v
o
l
u
m
e
 
(
[
l
e
n
g
t
h
 
 
 
 
 
w
i
d
t
h
2
]
/
2
)
Figure 2 In vivo growth of cell lines. 5 ´ 106 cells were innoculated into the
flank of BALB/c nu/nu mice and tumours measured 2–3 times a week.
Mutant cells formed tumours rapidly over a 7–10 day period. Each curve
shown represents mean ± SD of 7 mice 
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full length EGFR (DH-EGFR-E), mutant receptor (DH-E∆ 801-P) and empty
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of normoxic or hypoxic incubation were quantified by ELISA assay
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Figure 4 Effect of administration of anti-EGFRvIII antibody (DH8.3) in vitro
and in vivo. In vitro (A) 10 mg ml–1 of antibody was added to culture medium
of mutant (DH-E∆ 801-P) or wild-type (DH-EGFR-E) cells immediately prior to
16 hours of 0.1% hypoxia, and VEGF secretion compared to normoxic and
hypoxic cells without antibody. In vivo (B) 1 mg mouse–1 of DH8.3 or placebo
(PBS alone) was administered via tail vein injection on alternate days for 4
doses, commencing on the day of cell pellet inoculation (Day 0). The mean
tumour volume ± SD of 7 mice in each treatment group are shown. NS: not
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not suppress VEGF levels to below baseline (normoxic) values in
any cell line studied (Figure 6). Increasing the dose of LY 294002
(40 mm) failed to produce a larger reduction in VEGF levels to
below baseline levels (results not shown). 
IGF-1 was added to subconfluent cells cultured in serum-free
conditions for 8 hours prior to the addition of IGF-1 to minimize
the effects of other growth factors in culture medium. The dose of
IGF-1 chosen (100 ng ml–1) was based on published studies
demonstrating 50–100 ng ml–1 of IGF-1 saturated VEGF mRNA
and protein production in normoxic colo 205 cells (Warren et al,
1996). VEGF secretion in DH-E∆ 801-P cells grown under
normoxic conditions increased following addition of IGF-1 to
levels not significantly different from hypoxic values (P = 0.5).
Addition of IGF-1 to cells exposed to 16 hours hypoxia produced
no significant change in VEGF levels (P = 0.2) (Figure 7),
suggesting that the system was already maximally stimulated. In
empty vector control lines, IGF-1 did not increase VEGF secretion
under normoxic (P = 0.9) or hypoxic (P = 0.4) conditions. Pre-
incubation of cells with LY 294002 prior to addition of IGF-1,
partially inhibited the increase in VEGF secretion seen following
16 hours of hypoxia (data not shown). 
DISCUSSION 
EGFR is a transmembrane glycoprotein with an external binding
domain and an intracellular tyrosine kinase domain. Following
ligand binding, EGFR dimerizes and is autophosphorylated on
several tyrosine residues in the intracellular domain and initiates a
kinase cascade that activates members of the MAP kinase pathway
(Lacal and Carnero, 1994). In EGFRvIII, it is known that the loss
of exons 2–7 in the extracellular domain leads to the receptor
being constitutively active (Ekstrand et al, 1995). Cell lines estab-
lished from tumours that express endogenous EGFRvIII lose
expression of the variant receptor in vitro in tissue culture
(Humphrey et al, 1990). Increased tumorigenicity of human
glioblastoma cell line (U87) xenografts bearing a mutant plus full
length EGFR, compared to full length receptor alone, has been
previously shown (Niskikawa et al, 1994). Both observations
suggest a growth disadvantage for mutant cells in vitro, and/or
selection for mutant cells in vivo. We describe here enhanced
tumorigenicity in vivo of NIH3T3 cells transfected with mutant
EGFR as compared to full length EGFR, which occurred in the
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absence of any growth advantage in vitro. This provides a suitable
model for investigation of stimuli responsible for enhanced in vivo
growth. 
VEGF expression has been demonstrated in both malignant and
non-malignant cells, but is over-expressed in many malignant cells
(Takahashi et al, 1995). Stimulation of glioma cells expressing full
length EGFR by EGF resulted in a 25–125% increase in VEGF
secretion under normoxic conditions (Goldman et al, 1993). We
also demonstrated an increase in VEGF in EGF-stimulated wild-
type EGFR cells, but not in cells expressing mutant receptor.
Studies of VEGF distribution in tumours have shown localization
to necrotic and ischaemic areas, suggesting an interaction between
hypoxia and induction of VEGF (Minchenko et al, 1994). In vitro,
the relationship between VEGF and hypoxia has been demon-
strated in many cell lines. Given that EGFRvIII is expressed on a
high percentage of glioblastoma cells and glioblastoma multi-
forme is a highly anaplastic tumour with abundant proliferating
capillaries and paradoxically areas of necrosis, we investigated the
relationship between hypoxia, VEGF secretion, and expression of
mutant or full length EGFR. In the absence of exogenous EGF, full
length EGFR cells exposed to hypoxia produced only a minor
increase in VEGF compared to significant induction in mutant
cells. Hypoxia may therefore be a driving force for VEGF gene
expression in these cells. 
Expression of EGFvIII, compared to full length receptor, is
associated with lower levels of ERK (Antonyak et al, 1998),
higher levels of JNK activity, and constitutively active Pl3 kinase
(Moscatello et al, 1998). Pl3 kinase may be responsible for the
high levels of JNK activity and contribute to the transformed
phenotype in that inhibition of Pl3 kinase activity results in down-
regulation of JNK activity and correlated with loss of transformed
morphology (Moscatello et al, 1998). Kinase activity of wild-type
and mutated EGFR can be differentially blocked by various tyro-
sine kinase inhibitors, consistent with the idea that the conforma-
tional changes induced by ectodomain deletion in EGFRvIII
differs from ligand activated wild-type EGFR (Han et al, 1996). 
PI3 kinase is involved in signal transduction that is activated by
ras and other dominant oncogenes and growth factors, and may
play a role in regulating the angiogenic switch (Arbieser et al,
1997). Serine/threonine kinase Akt/protein kinase B (PKB) is a
major target of Pl3 kinase-mediated signals (Gerber et al, 1998).
Akt/PKB is rapidly activated by insulin and a number of growth
factors including platelet-derived growth factor, EGF and IGF-1
(Franke et al, 1997; Holst et al, 1998). Using both wortmannin and
LY294002, reduction in VEGF protein secretion was seen in
mutant cells in response to hypoxia but not basal levels, suggesting
that Pl3 kinase has a major role in the hypoxic response, but
constitutive activation alone was insufficient. Giaccia showed
transfection of Pl3 kinase enhanced hypoxic induction of a
reporter construct with hypoxia inducible factor-1 alpha site,
although the mechanism is unknown (Mazure et al, 1997). 
A recent study showed a role for Pl3 kinase in regulation of
VEGF by the wild-type and truncation mutant EGFr (Maity et al,
2000). However in that study Pl3 kinase inhibition down-regulated
basal VEGF but had no effect on hypoxia-inducible VEGF, in
contrast to our study. 
VEGF expression is regulated by numerous cytokines and
growth factors including interleukins 1 and 6, transforming growth
factor beta, and basic fibroblast growth factor, the effect of which
is dependent on the tumour system studied (Akagi et al, 1998).
IGF-1, a homologue of insulin, and its receptor contribute to
neoplastic transformation and the development of tumorigenicity
through autocrine and paracrine mechanisms (Baserga, 1995;
Warren et al, 1996) and is an important mitogen for many tumour
types. It shares with hypoxia and insulin the ability to induce
expression of genes encoding for the glucose transporters (Glut 1
and 3), erythropoietin and VEGF (Zelzer et al, 1998). Basal levels
of VEGF, whilst varying between cell lines, have been shown to
increase following stimulation with IGF-1 in cancer cells and non-
malignant cell lines (Singh and Rubin, 1993; Warren et al, 1996;
Akagi et al, 1998). This response has been reported in lines in
which it induced a proliferative response and in lines in which it
did not, and therefore appears to be distinct from any effects on
cell proliferation (Zelzer et al, 1998). In transformed NIH3T3 cells
expressing mutant EGF receptor, IGF-1 increased the secretion of
VEGF levels under normoxic conditions to levels equivalent to
hypoxic levels. There was no significant further increase in
hypoxic cells stimulated with IGF-1, suggesting both operated via
a final common pathway. This pathway was also inhibited by Pl3
kinase inhibitors. These data show that mutant EGFR is associated
with enhanced signalling by Pl3 kinase that synergizes with
hypoxia or IGF-1 under normoxic conditions to regulate VEGF. 
In vitro blocking antibodies inhibited hypoxic induction of
VEGF suggesting that constitutive activation was reversed or the
mutant receptor down-regulated. In vivo this correlated with
reduced tumour growth. Median VEGF levels were also lower in
the treated group as were the lowest and highest VEGF levels
compared to the controls, although this did not reach statistical
significance. The mechanism of enhanced tumorigenicity in vivo
of mutant EGFRvIII cells does not appear to be directly due to an
effect on increased cell growth in that when removed from exoge-
nous stimuli in vitro, no differences in growth are observed, but
rather reflects interactions between environmental stimuli and
cells bearing mutant receptor. Tumour microenvironment is likely
to play a critical role in regulating cell viability. Regions of low
oxygen tension are common to solid tumours and appear to signal
an increase in angiogenic gene expression and increase apoptosis.
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Figure 7 Effects of IGF-1 on VEGF secretion. Subconfluent cells
expressing the mutant EGFR receptor (DH-E∆ 801-P) or empty vector control
(DL-12) were placed in serum-free medium for 8 hours prior to addition of
IGF-1 100 ng ml–1 and incubation for 16 hours in hypoxia or normoxia.
Supernatant was collected and VEGF quantified via ELISA assay.
Mean ± SD of triplicate results are shown The in vitro results provide a potential explanation for the in vivo
growth differences, in that hypoxia could synergize with mutant
EGFR, or in non-hypoxic areas with paracrine growth factors to
enhance VEGF production. 
Mutant EGFr may also interact with other oncogenes, particu-
larly H-ras to induce VEGF. Although in our study there was no
effect of mutant EGFr on basal VEGF levels, in a cell line with
high Ras activity there was an increase in normoxic VEGF levels
(Feldkamp et al, 1999). The increase induction of VEGF by
hypoxia was much less than in our experiments, 25% greater than
the parent cell line. Our study shows the differing effects in a low
versus the high Ras background. 
Mutated EGFR thus provides a potential target for tumour-
specific therapy, although antibodies against wild-type receptors
have also shown selective effects against tumours (Mendelsohn,
1998). The results presented here show that one mechanism by
which oncogenes may function is enhancement of response to
hypoxia, without change in basal VEGF expression, in contrast to
previous results with wild-type EGF receptor. It may be that the
splice variant is specifically selected by the hypoxic micro-
environment as are mutations of p53 (Graeber et al, 1996). We
have previously shown that the hypoxic stress pathway regulated
by hypoxic inducible factor-1 alpha is critical for in vivo growth of
tumours (Maxwell et al, 1997) and interactions with mutant EGFR
may provide a molecular mechanism for amplifying this hypoxic
switch. This study supports both the use of anti-EGFR antibodies
and Pl3 kinase inhibitors to block in vivo tumour growth mediated
by mutant EGFR. 
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